AREVA
Live / Applied — Statement of use — response to non-final action entered (as of 11 Sept 2026)
What this means for you
Not registered yet, but its 25 Mar 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98466073
- Mark type
- Stylized text
- Filed
- 25 Mar 2024
- Published for opposition
- 26 Nov 2024
- Attorney of record
- Michael S. Hargis
Goods and services
- Class 005 — Pharmaceuticals: House mark for pharmaceutical preparations for the treatment of cancer, heart failure, heart disease, and hypertension; House mark for pharmaceutical preparations for use in gene therapy; House mark for pharmaceutical preparations for the treatment of cancer, heart failure, heart disease, and hypertension, in the form of oncology injectables and oral solids
Owner
- Areva Pharmaceuticals Inc., Georgetown, IN, US
- Areva Pharmaceuticals Inc., Georgetown, IN, US
Prosecution history
- 11 Sept 2026 — AMENDMENT FROM APPLICANT ENTERED
- 11 Sept 2026 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 11 Sept 2026 — ASSIGNED TO LIE
- 09 Sept 2026 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 01 Jun 2026 — APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
- 01 Jun 2026 — APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
- 13 Mar 2026 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 13 Mar 2026 — NON-FINAL ACTION E-MAILED
- 13 Mar 2026 — SU - NON-FINAL ACTION - WRITTEN
- 23 Feb 2026 — DATA MODIFICATION COMPLETED
- 20 Feb 2026 — STATEMENT OF USE PROCESSING COMPLETE
- 15 Jul 2025 — USE AMENDMENT FILED
- 19 Jan 2026 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 15 Jul 2025 — TEAS STATEMENT OF USE RECEIVED
- 15 Jul 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT